Chongqing Precision Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
41 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD123 CAR-T cell therapy / Chongqing Precision Biotech
NCT04265963: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
45
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24
NCT04272125: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
40
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24
BCMA CAR-T cell therapy / Chongqing Precision Biotech
NCT04271644: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting
1/2
80
RoW
BCMA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
12/26
07/27
NCT04272151: Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
40
RoW
BCMA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell
12/23
07/24
NCT04776330: A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting
1/2
80
RoW
BCMA targeted prime CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
12/26
07/27
priscabtagene autoleucel (pCAR-19B) / Chongqing Precision Biotech
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Recruiting
2
100
RoW
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
12/24
07/25
NCT04271410: CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Recruiting
1/2
80
RoW
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
12/23
07/24
NCT04271800: Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Recruiting
1/2
40
RoW
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
12/23
07/24
CTR20191243: Safety and tolerability study of pCAR-19B in CD19-positive R/R B-ALL

Completed
1
12
China
pCAR-19B - Chongqing Precision Biotech
Chongqing Precision Biotechnology Co., Ltd.
CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia
 
 
NCT04888442: Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Recruiting
1
18
RoW
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
01/22
03/22
NCT05420493: Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Recruiting
1
54
RoW
CAR-T cells
Chongqing Precision Biotech Co., Ltd
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma
09/24
09/25
NCT06180174: Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Recruiting
1
24
RoW
MC-1-50
Chongqing Precision Biotech Co., Ltd, Peking University Cancer Hospital & Institute
B Cell Lymphoma, Non Hodgkin Lymphoma
12/25
12/26
NCT06222853: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Recruiting
1
18
RoW
anti-CD19-CAR-T cells
The Children's Hospital of Zhejiang University School of Medicine, Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus, CAR-T Cell Therapy
12/26
12/26
NCT06569472: Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

Recruiting
1
10
RoW
CD19-targetd CAR-T
Chongqing Precision Biotech Co., Ltd
Juvenile Dermatomyositis
07/27
07/28
NCT06641024: Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

Not yet recruiting
1
24
RoW
MC-1-50
Chongqing Precision Biotech Co., Ltd, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
11/27
11/39
NCT06892145: Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Not yet recruiting
1
12
RoW
MC-1-50
Chongqing Precision Biotech Co., Ltd, Second Affiliated Hospital, School of Medicine, Zhejiang University
Systemic Lupus Erythematosus (SLE), Refractory
05/26
02/28
NCT06056921: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Recruiting
1
24
RoW
CD19 targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
12/25
08/26
C-13-60 / Chongqing Precision Biotech
NCT04348643: Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Recruiting
1/2
40
RoW
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Gastric Cancer, Breast Cancer
12/23
04/24
NCT05538195: Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Recruiting
1/2
60
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreatic Cancer
12/24
06/25
NCT06006390: CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Recruiting
1/2
60
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, Shanxi Bethune Hospital
Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer, Lung Cancer, Breast Cancer
12/25
08/26
NCT05415475: Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Recruiting
1
36
RoW
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Tumor, Recurrent Cancer
09/24
09/25
NCT06126406: Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Recruiting
1
60
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, First Affiliated Hospital of Wannan Medical College
Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas Cancer
12/25
12/26
PBC039, NCT05396300: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Completed
1
43
RoW
CEA CAR-T cells
Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Tumor, Recurrent Cancer
06/24
06/24
NCT06821048: Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Recruiting
1
50
RoW
Intravenous infusion of FAST CEA-targeted CAR-T, Intraperitoneal infusion of FAST CEA-targeted CAR-T
Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Metastatic Cancer, Recurrent Cancer
06/26
12/27
NCT06768151: A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Recruiting
1
48
RoW
Targeted CEA CAR-T
Chongqing Precision Biotech Co., Ltd
Advanced Lung Cancer
12/26
12/27
NCT06945523: Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Recruiting
1
60
RoW
Targeted CEA CAR-T
Chongqing Precision Biotech Co., Ltd
Advanced Lung Cancer
12/27
04/28
NCT06010862: Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Recruiting
1
36
RoW
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd, The First Affiliated Hospital of Nanchang University
Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer, Cholangiocarcinoma, Lung Cancer, Breast Cancer
12/25
09/26
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Recruiting
1
30
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, Zhejiang University
Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer
12/26
12/27
CD19 and CD22 targeted prime CAR-T / Chongqing Precision Biotech
NCT04781634: A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Recruiting
1/2
40
RoW
CD19 and CD22 targeted prime CAR-T cells
Chongqing Precision Biotech Co., Ltd
B-ALL
12/26
07/27
NCT04782193: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Recruiting
1/2
40
RoW
CD19 and CD22 targeted prime CAR- T cells
Chongqing Precision Biotech Co., Ltd
B Cell Lymphoma
12/23
07/24
C-4-29 / Chongqing Precision Biotech
CTR20210564: Preliminary observation of the long-term effectiveness of C-4-29 cell preparation in the treatment of relapsed/refractory multiple myeloma

Recruiting
1
18
China
C-4-29 - Chongqing Precision Biotech
Chongqing Precision Biotechnology Co., Ltd.
Relapsed/refractory multiple myeloma
 
 
NCT04861480: Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Enrolling by invitation
1
18
RoW
C-4-29 Cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
12/23
07/24
ChiCTR2200056457: Phase I clinical Trial of chimeric antigen receptor T lymphocyte (C-4-29) preparation in patients with recurrent/refractory multiple myeloma

Not yet recruiting
1
9
 
Venous reinfusion of of 1×10^6/kg CAR+ cells; Venous reinfusion of of 3×10^6/kg CAR+ cells; Venous reinfusion of of 6×10^6/kg CAR+ cells
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/West China Hospital of Sichuan University; Chongqing Precision Biotechnology Co., Ltd, Enterprise self financing
recurrent/refractory multiple myeloma
 
 
CD70 CAR-T / Chongqing Precision Biotech
NCT05420519: Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Recruiting
1
24
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer
12/23
12/24
NCT05420545: A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting
1
36
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
12/23
12/24
NCT06215950: A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Recruiting
1
36
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer, Gynecologic Cancer
12/26
12/27
NCT05518253: A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting
1
30
RoW
CD70 CAR-T cells
Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
05/26
05/27
NCT05468190: A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Recruiting
1
48
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
07/24
07/25
NCT06934447: Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

Recruiting
1
18
RoW
anti-BCMA/CD70-CAR-T cells
The Children's Hospital of Zhejiang University School of Medicine, Chongqing Precision Biotech Co., Ltd
CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
04/28
04/28
NCT06010875: A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting
1
48
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd, The First Affiliated Hospital of Nanchang University
Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
12/25
09/26
PB103 / Chongqing Precision Biotech
NCT04616209: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
24
RoW
donor-derived NK cell infusion
Precision Biotech Taiwan Corp., Tri-Service General Hospital
Non-small Cell Lung Cancer
12/27
12/27
anti-CD19 UCAR-NK / Chongqing Precision Biotech
No trials found
LstCAR019 / Chongqing Precision Biotech
No trials found
C-13-90 / Chongqing Precision Biotech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD123 CAR-T cell therapy / Chongqing Precision Biotech
NCT04265963: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
45
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24
NCT04272125: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
40
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24
BCMA CAR-T cell therapy / Chongqing Precision Biotech
NCT04271644: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting
1/2
80
RoW
BCMA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
12/26
07/27
NCT04272151: Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
40
RoW
BCMA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell
12/23
07/24
NCT04776330: A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting
1/2
80
RoW
BCMA targeted prime CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
12/26
07/27
priscabtagene autoleucel (pCAR-19B) / Chongqing Precision Biotech
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Recruiting
2
100
RoW
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
12/24
07/25
NCT04271410: CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Recruiting
1/2
80
RoW
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
12/23
07/24
NCT04271800: Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Recruiting
1/2
40
RoW
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
12/23
07/24
CTR20191243: Safety and tolerability study of pCAR-19B in CD19-positive R/R B-ALL

Completed
1
12
China
pCAR-19B - Chongqing Precision Biotech
Chongqing Precision Biotechnology Co., Ltd.
CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia
 
 
NCT04888442: Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Recruiting
1
18
RoW
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
01/22
03/22
NCT05420493: Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Recruiting
1
54
RoW
CAR-T cells
Chongqing Precision Biotech Co., Ltd
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma
09/24
09/25
NCT06180174: Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Recruiting
1
24
RoW
MC-1-50
Chongqing Precision Biotech Co., Ltd, Peking University Cancer Hospital & Institute
B Cell Lymphoma, Non Hodgkin Lymphoma
12/25
12/26
NCT06222853: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Recruiting
1
18
RoW
anti-CD19-CAR-T cells
The Children's Hospital of Zhejiang University School of Medicine, Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus, CAR-T Cell Therapy
12/26
12/26
NCT06569472: Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

Recruiting
1
10
RoW
CD19-targetd CAR-T
Chongqing Precision Biotech Co., Ltd
Juvenile Dermatomyositis
07/27
07/28
NCT06641024: Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

Not yet recruiting
1
24
RoW
MC-1-50
Chongqing Precision Biotech Co., Ltd, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
11/27
11/39
NCT06892145: Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Not yet recruiting
1
12
RoW
MC-1-50
Chongqing Precision Biotech Co., Ltd, Second Affiliated Hospital, School of Medicine, Zhejiang University
Systemic Lupus Erythematosus (SLE), Refractory
05/26
02/28
NCT06056921: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Recruiting
1
24
RoW
CD19 targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
12/25
08/26
C-13-60 / Chongqing Precision Biotech
NCT04348643: Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Recruiting
1/2
40
RoW
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Gastric Cancer, Breast Cancer
12/23
04/24
NCT05538195: Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Recruiting
1/2
60
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreatic Cancer
12/24
06/25
NCT06006390: CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Recruiting
1/2
60
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, Shanxi Bethune Hospital
Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer, Lung Cancer, Breast Cancer
12/25
08/26
NCT05415475: Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Recruiting
1
36
RoW
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Tumor, Recurrent Cancer
09/24
09/25
NCT06126406: Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Recruiting
1
60
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, First Affiliated Hospital of Wannan Medical College
Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas Cancer
12/25
12/26
PBC039, NCT05396300: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Completed
1
43
RoW
CEA CAR-T cells
Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Tumor, Recurrent Cancer
06/24
06/24
NCT06821048: Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Recruiting
1
50
RoW
Intravenous infusion of FAST CEA-targeted CAR-T, Intraperitoneal infusion of FAST CEA-targeted CAR-T
Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd
Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Metastatic Cancer, Recurrent Cancer
06/26
12/27
NCT06768151: A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Recruiting
1
48
RoW
Targeted CEA CAR-T
Chongqing Precision Biotech Co., Ltd
Advanced Lung Cancer
12/26
12/27
NCT06945523: Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Recruiting
1
60
RoW
Targeted CEA CAR-T
Chongqing Precision Biotech Co., Ltd
Advanced Lung Cancer
12/27
04/28
NCT06010862: Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Recruiting
1
36
RoW
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd, The First Affiliated Hospital of Nanchang University
Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer, Cholangiocarcinoma, Lung Cancer, Breast Cancer
12/25
09/26
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Recruiting
1
30
RoW
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd, Zhejiang University
Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer
12/26
12/27
CD19 and CD22 targeted prime CAR-T / Chongqing Precision Biotech
NCT04781634: A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Recruiting
1/2
40
RoW
CD19 and CD22 targeted prime CAR-T cells
Chongqing Precision Biotech Co., Ltd
B-ALL
12/26
07/27
NCT04782193: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Recruiting
1/2
40
RoW
CD19 and CD22 targeted prime CAR- T cells
Chongqing Precision Biotech Co., Ltd
B Cell Lymphoma
12/23
07/24
C-4-29 / Chongqing Precision Biotech
CTR20210564: Preliminary observation of the long-term effectiveness of C-4-29 cell preparation in the treatment of relapsed/refractory multiple myeloma

Recruiting
1
18
China
C-4-29 - Chongqing Precision Biotech
Chongqing Precision Biotechnology Co., Ltd.
Relapsed/refractory multiple myeloma
 
 
NCT04861480: Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Enrolling by invitation
1
18
RoW
C-4-29 Cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
12/23
07/24
ChiCTR2200056457: Phase I clinical Trial of chimeric antigen receptor T lymphocyte (C-4-29) preparation in patients with recurrent/refractory multiple myeloma

Not yet recruiting
1
9
 
Venous reinfusion of of 1×10^6/kg CAR+ cells; Venous reinfusion of of 3×10^6/kg CAR+ cells; Venous reinfusion of of 6×10^6/kg CAR+ cells
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/West China Hospital of Sichuan University; Chongqing Precision Biotechnology Co., Ltd, Enterprise self financing
recurrent/refractory multiple myeloma
 
 
CD70 CAR-T / Chongqing Precision Biotech
NCT05420519: Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Recruiting
1
24
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer
12/23
12/24
NCT05420545: A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting
1
36
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
12/23
12/24
NCT06215950: A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Recruiting
1
36
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer, Gynecologic Cancer
12/26
12/27
NCT05518253: A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting
1
30
RoW
CD70 CAR-T cells
Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
05/26
05/27
NCT05468190: A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Recruiting
1
48
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
07/24
07/25
NCT06934447: Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

Recruiting
1
18
RoW
anti-BCMA/CD70-CAR-T cells
The Children's Hospital of Zhejiang University School of Medicine, Chongqing Precision Biotech Co., Ltd
CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
04/28
04/28
NCT06010875: A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting
1
48
RoW
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd, The First Affiliated Hospital of Nanchang University
Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
12/25
09/26
PB103 / Chongqing Precision Biotech
NCT04616209: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
24
RoW
donor-derived NK cell infusion
Precision Biotech Taiwan Corp., Tri-Service General Hospital
Non-small Cell Lung Cancer
12/27
12/27
anti-CD19 UCAR-NK / Chongqing Precision Biotech
No trials found
LstCAR019 / Chongqing Precision Biotech
No trials found
C-13-90 / Chongqing Precision Biotech
No trials found

Download Options